<DOC>
	<DOCNO>NCT01263028</DOCNO>
	<brief_summary>Hypothesis : The supplementation Ergocalciferol ( Vitamin D2 ) Vitamin D deficiency Chronic Kidney Disease population require recombinant human erythropoietin treatment anemia relate kidney disease reduce dose erythropoietin require maintain nonanemic state .</brief_summary>
	<brief_title>Effects Ergocalciferol Erythropoetin Stimulating Agent Dose</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic kidney disease Age : &gt; 18yo Stable Hemoglobin ( Hgb ) 1 month stable dose erythropoietin 1 month ( define erythropoietin dose within 15 % previous month erythropoietin dose ) Unchanged maintenance oral intravenous ( IV ) iron therapy 1 month Serum 25hydroxy Vitamin D level &lt; 30 ng/mL History 25hydroxy Vitamin D level &lt; 30 ng/mL currently ergocalciferol replacement On hemodialysis Chronic kidney disease 5 Hypercalcemic ( Calcium level &gt; 11mg/dL ) Pregnant female Iron deficient ( iron saturation &lt; 20 % , Ferritin &lt; 100ng/mL ) Presence active malignancy Presence active infection Presence active inflammatory property Presence blood dyscrasia Active bleed bleeding within past 3 month ( menses ) B12 deficiency Folate deficiency Blood transfusion participation Parathyroid level exceed expect level allow stage subject Chronic kidney disease ( Target Parathyroid : Chronic kidney disease 3 3570 pg/mL , Chronic kidney disease 4 70110 pg/mL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>